Animal trials, including the analysis of the liver and kidneys, which showed no signs of antigenicity or inflammation, solidified the therapeutic benefits of dP@mVLP/RNAic-MET pretreatment followed by oral TMZ compared with another synthesized molecule mVLP/RNAic-MET pretreatment with TMZ, which proved ineffective, confirming gene therapy and chemotherapy combination as a unique and considerable approach to brain tumor treatment, which should be further explored (Pang et al., 2019). The gene discussed is MET; the disease is brain neoplasm.